Nordic Issuing

Ongoing case

Expres2ion Biotech Holding AB

Back to all cases

Expres2ion Biotech Holding AB

1 Jun - 31 Aug 2020Exercising of warrants

Expres2ion Biotech Holding AB has developed a platform, Expres2, for fast pre clinical and clinical development and solid production of complex proteins for new vaccnies and diagnoses. Expres2 is regulatory validated to be clinically provided.

The patented ExpreS2 protein expression system is built for optimal discovery, preclinical development and GMP production of hard-to-express proteins used in vaccines and vaccine-like treatments.

The system is built upon non-viral fruit fly cells and has the ability to quickly establish stable polyclonal pools that provide high protein expression levels. Introduction of the protein to express in the system is conducted through the use of vector DNA containing a constitutive proprietary hybrid promoter.

Read more on the company's website


The offer in summary

Assignment: Exercising of staff warrants

Subscription period: 1 June - 31 August 2020

Documents

Disclaimer

Due to restrictions in applicable law in the United States, Canace, Australia, Hong Kong, Singapore, South Africa, Switzerland, New Zealand, Japan or other countries where participation requires further prospectuses, registrations or actions other than those under Swedish law, the offer to subscribe for securities in this offer is not directed at persons or others with registered address in any of these countries.